Frontiers in Oncology (Jul 2022)
Prognostic Value of Thrombocytopenia in Myelodysplastic Syndromes After Hematopoietic Stem Cell Transplantation
- Hong Wang,
- Hong Wang,
- Hong Wang,
- Jiaqian Qi,
- Jiaqian Qi,
- Jiaqian Qi,
- Xueqian Li,
- Xueqian Li,
- Xueqian Li,
- Tiantian Chu,
- Tiantian Chu,
- Tiantian Chu,
- Huiying Qiu,
- Huiying Qiu,
- Huiying Qiu,
- Chengcheng Fu,
- Chengcheng Fu,
- Chengcheng Fu,
- Xiaowen Tang,
- Xiaowen Tang,
- Xiaowen Tang,
- Changgeng Ruan,
- Changgeng Ruan,
- Changgeng Ruan,
- Depei Wu,
- Depei Wu,
- Depei Wu,
- Depei Wu,
- Yue Han,
- Yue Han,
- Yue Han,
- Yue Han
Affiliations
- Hong Wang
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
- Hong Wang
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
- Hong Wang
- Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
- Jiaqian Qi
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
- Jiaqian Qi
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
- Jiaqian Qi
- Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
- Xueqian Li
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
- Xueqian Li
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
- Xueqian Li
- Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
- Tiantian Chu
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
- Tiantian Chu
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
- Tiantian Chu
- Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
- Huiying Qiu
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
- Huiying Qiu
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
- Huiying Qiu
- Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
- Chengcheng Fu
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
- Chengcheng Fu
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
- Chengcheng Fu
- Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
- Xiaowen Tang
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
- Xiaowen Tang
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
- Xiaowen Tang
- Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
- Changgeng Ruan
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
- Changgeng Ruan
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
- Changgeng Ruan
- Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
- Depei Wu
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
- Depei Wu
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
- Depei Wu
- Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
- Depei Wu
- State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China
- Yue Han
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
- Yue Han
- Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
- Yue Han
- Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China
- Yue Han
- State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China
- DOI
- https://doi.org/10.3389/fonc.2022.940320
- Journal volume & issue
-
Vol. 12
Abstract
Prolonged isolated thrombocytopenia (PT) is a common complication affecting the outcome of stem cell transplantation. In this study, we undertook a real-world study of 303 myelodysplastic syndrome (MDS) patients who received allogeneic hematopoietic stem cell transplantation (HSCT) between December 2007 and June 2018. 28.4% of MDS patients suffered from PT after HSCT. Survival analysis indicated that PT was associated with worse overall survival (OS) in MDS patients. The 2-year and 5-year OS in MDS patients with PT after HSCT were 49% and 47%, significantly worse than that of 68% and 60% in patients without PT (P=0.005). For RFS, patients with PT did not have an increased risk of disease relapse (P=0.964). After multivariate adjustment, PT was proved to be the independent risk factor associated with the worse OS (HR 1.49, 95% CI 1.00-2.21, P =0.048). We further analyzed risk factors associated with the occurrence of PT in MDS patients. Multiple logistic regression identified grade II-IV aGVHD, extensive chronic GVHD, hemorrhagic cystitis, and CMV activation as significant risk factors for developing PT. Among these variables, the Odds Ratio (OR) of grade II-IV aGVHD was the highest (P =0.001, OR: 2.65, 95% CI: 1.51-4.64). These data indicated the prognostic value of PT in MDS after HSCT. The identification of risk factors for PT may help improve patient management and lead to the design of effective treatment strategies.
Keywords
- hematopoietic stem cell transplantation
- myelodysplastic syndrome
- prognosis
- thrombocytopenia
- risk factor
